Is It Time to Introduce PET/CT in Rectal Cancer Guidelines?
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
20
6
2020
medline:
23
10
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
At the moment, international guidelines for rectal cancer suggest to consider F-FDG PET/CT scan in a few conditions: (1) at disease presentation in case of suspected or proven metastatic synchronous adenocarcinoma with potentially curable M1 disease; (2) in the recurrence workup for serial carcinoembryonic antigen level elevation; (3) in the recurrence workup with metachronous metastases documented by CT, MRI, or biopsy; (4) in case of strong contraindication to IV contrast agent administration; and (5) to evaluate an equivocal finding on a contrast-enhanced CT or MRI. PET/CT is not indicated in the follow-up or surveillance of rectal cancer. On the other hand, an attentive evaluation of the literature shows that PET/CT may also be used in some circumstances with significant levels of diagnostic accuracy. This review article aims to emphasize differences between current international guidelines and scientific literature in the role of PET/CT in rectal cancer.
Identifiants
pubmed: 32558716
doi: 10.1097/RLU.0000000000003132
pii: 00003072-202008000-00005
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
611-617Références
Key Statistics for Colorectal Cancer. Available at: www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html. Accessed March 26, 2020.
Desch CE, Benson AB 3rd, Smith TJ, et al. Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999;17:1312.
Byers T, Levin B, Rothenberger D, et al. American Cancer Society Guidelines for Screening and Surveillance for Early Detection of Colorectal Polyps and Cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin. 1997;47:154–160.
Castells A, Bessa X, Quintero E, et al. Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst. 2013;105:878–886.
Loberg M, Kalager M, Holme O, et al. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med. 2014;371:799–807.
Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014;348:g2467.
Heusner TA, Hahn S, Hamami ME, et al. Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development. Eur Radiol. 2009;19:2171–2179.
Curvo-Semedo L. Rectal cancer: staging. Magn Reson Imaging Clin N Am. 2020;28:105–115.
Tudyka V, Blomqvist L, Beets-Tan RG, et al. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2014;40:469–475.
Marone P, de Bellis M, D'Angelo V, et al. Role of endoscopic ultrasonography in the loco-regional staging of patients with rectal cancer. World J Gastrointest Endosc. 2015;7:688–701.
Surace A, Ferrarese A, Gentile V, et al. Learning curve for endorectal ultrasound in young and elderly: lights and shades. Open Med (Wars). 2016;11:418–425.
Cawthorn SJ, Parums DV, Gibbs NM, et al. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet. 1990;335:1055–1059.
Glimelius B, Beets-Tan R, Blomqvist L, et al. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 2011;29:2142–2143.
Schurink NW, Lambregts DMJ, Beets-Tan RGH. Diffusion-weighted imaging in rectal cancer: current applications and future perspectives. Br J Radiol. 2019;92:20180655.
Winter L, Bruhn H, Langrehr J, et al. Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution. Acta Radiol. 2007;48:379–387.
Taylor FG, Swift RI, Blomqvist L, et al. A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. AJR Am J Roentgenol. 2008;191:1827–1835.
Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28:1465–1475.
Sahni VA, Silveira PC, Sainani NI, et al. Impact of a structured report template on the quality of MRI reports for rectal cancer staging. AJR Am J Roentgenol. 2015;205:584–588.
Koh DM, Chau I, Tait D, et al. Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2008;71:456–461.
Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am. 2002;31:827–839.
NCCN Clinical Practice Guidelines in Oncology Rectal Cancer Version 2.2020, page MS-10. Available at: www.nccn.org. Accessed March 26, 2020.
Glynne-Jones R, Wyrwicz L, Tiret E, et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv263.
van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European Consensus Conference Colon & Rectum. Eur J Cancer. 2014;50:1.e1–1.e34.
Mukai M, Sadahiro S, Yasuda S, et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep. 2000;7:85–87.
Mainenti PP, Iodice D, Segreto S, et al. Colorectal cancer and 18FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging? World J Gastroenterol. 2011;17:1427–1433.
Bae SU, Won KS, Song BI, et al. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer. Cancer Imaging. 2018;18:32.
Gearhart SL, Frassica D, Rosen R, et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol. 2006;13:397–404.
Tateishi U, Maeda T, Morimoto T, et al. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:1627–1634.
Kunawudhi A, Sereeborwornthanasak K, Promteangtrong C, et al. Value of FDG PET/contrast-enhanced CT in initial staging of colorectal cancer - comparison with contrast-enhanced CT. Asian Pac J Cancer Prev. 2016;17:4071–4075.
Kam MH, Wong DC, Siu S, et al. Comparison of magnetic resonance imaging-fluorodeoxy- glucose positron emission tomography fusion with pathological staging in rectal cancer. Br J Surg. 2010;97:266–268.
Bailey JJ, Jordan EJ, Burke C, et al. Does extended PET acquisition in PET/MRI rectal cancer staging improve results? AJR Am J Roentgenol. 2018;211:896–900.
ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?cond=rectal+cancer&term=staging+PET%2FMRI&cntry=&state=&city=&dist=. Accessed March 30, 2020.
Hotta M, Minamimoto R, Yano H, et al. Diagnostic performance of 18F-FDG PET/CT using point spread function reconstruction on initial staging of rectal cancer: a comparison study with conventional PET/CT and pelvic MRI. Cancer Imaging. 2018;18:4.
Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology. 2005;237:123–131.
Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257:674–684.
Frankel TL, Gian RK, Jarnagin WR. Preoperative imaging for hepatic resection of colorectal cancer metastasis. J Gastrointest Oncol. 2012;3:11–18.
Bamba Y, Itabashi M, Kameoka S. Value of PET/CT imaging for diagnosing pulmonary metastasis of colorectal cancer. Hepatogastroenterology. 2011;58:1972–1974.
Guerrera F, Renaud S, Schaeffer M. Low accuracy of computed tomography and positron emission tomography to detect lung and lymph node metastases of colorectal cancer. Ann Thorac Surg. 2017;104:1194–1199.
Valentini V, Gambacorta MA, Barbaro B, et al. International Consensus Guidelines on Clinical Target Volume Delineation in Rectal Cancer. Radiother Oncol. 2016;120:195–201.
Burbach JP, den Harder AM, Intven M, et al. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;113:1–9.
Macchia G, Gambacorta MA, Masciocchi C, et al. Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: a population study on 2094 patients. Clin Transl Radiat Oncol. 2017;4:8–14.
Lupattelli M, Matrone F, Gambacorta MA, et al. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer: short-term results of a multicentric study. Radiat Oncol. 2017;12:139.
Maas M, Lambregts DM, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015;22:3873–3880.
Meng X, Huang Z, Wang R, et al. Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Biosci Trends. 2014;8:11–23.
Li QW, Zheng RL, Ling YH, et al. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study. Abdom Radiol (NY). 2016;41:1448–1455.
Lee MA, Cho SH, Seo AN, et al. Modified 3-point MRI-based tumor regression grade incorporating DWI for locally advanced rectal cancer. Am J Roentgenol. 2017;209:1247–1255.
van der Valk MJM, Hilling DE, Bastiaannet E, et al.; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–2545.
Goodman KA, Patton CE, Fisher GA, et al. Appropriate customization of radiation therapy for stage II and III rectal cancer: executive summary of an ASTRO clinical practice statement using the RAND/UCLA appropriateness method. Pract Radiat Oncol. 2016;6:166–175.
Patel DA, Chang ST, Goodman KA, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat. 2007;6:31–36.
Krengli M, Cannillo B, Turri L, et al. Target volume delineation for preoperative radiotherapy of rectal cancer: inter-observer variability and potential impact of FDG-PET/CT imaging. Technol Cancer Res Treat. 2010;9:393–398.
Agarwal A, Marcus C, Xiao J, et al. FDG PET/CT in the management of colorectal and anal cancers. AJR Am J Roentgenol. 2014;203:1109–1119.
Bulens P, Thomas M, Deroose CM, et al. PET imaging in adaptive radiotherapy of gastrointestinal tumors. Q J Nucl Med Mol Imaging. 2018;62:385–403.
Gwynne S, Mukherjee S, Webster R, et al. Imaging for target volume delineation in rectal cancer radiotherapy—a systematic review. Clin Oncol (R Coll Radiol). 2012;24:52–63.
Jingu K, Ariga H, Kaneta T, et al. Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer. 2010;10:127.
Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423–1426.
Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys. 2007;69:155–162.
David JM, Gresham G, Jabbour SK, et al. Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer. J Gastrointest Oncol. 2018;9:641–649.
Devic S. Towards biological target volumes definition for radiotherapy treatment planning: quo vadis PET/CT? J Nucl Med Radiat Ther. 2013;4:158. Available at: https://www.semanticscholar.org/paper/Towards-Biological-Target-Volumes-Definition-for-Devic/ba9c9b0ad867e787a166f21be446c7ca4b8e87e3. Accessed May 29, 2020.
Passoni P, Fiorino C, Slim N, et al. Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor. Int J Radiat Oncol Biol Phys. 2013;87:67–72.
Raso R, Scalco E, Fiorino C, et al. Assessment and clinical validation of margins for adaptive simultaneous integrated boost in neo-adjuvant radiochemotherapy for rectal cancer. Phys Med. 2015;31:167–172.
Maggiulli E, Fiorino C, Passoni P, et al. Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: implications for adaptive dose escalation strategies. Acta Oncol. 2012;51:318–324.
Maffione AM, Marzola MC, Capirci C, et al. Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am J Roentgenol. 2015;204:1261–1268.
Rymer B, Curtis NJ, Siddiqui MRS, et al. FDG PET/CT can assess the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy: evidence from meta-analysis and systematic review. Clin Nucl Med. 2016;41:371–375.
Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer–the RAPIDO trial. BMC Cancer. 2013;13:279.
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT). ClinicalTrials.gov Identifier: NCT01515787. Available at: https://clinicaltrials.gov/ct2/show/NCT01515787. Accessed May 29, 2020.
Memon S, Lynch AC, Akhurst T, et al. Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. Ann Surg Oncol. 2014;21:3598–3607.
de Jong EA, ten Berge JC, Dwarkasing RS, et al. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis. Surgery. 2016;159:688–699.
Wu LM, Zhu J, Hu J, et al. Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer? Int J Colorectal Dis. 2013;28:1225–1238.
Memon S, Lynch AC, Bressel M, et al. Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis. 2015;17:748–761.
Gollub MJ, Hotker AM, Woo KM, et al. Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdom Radiol (NY). 2018;43:1575–1582.
Huh JW, Kwon SY, Lee JH, et al. Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer. J Cancer Res Clin Oncol. 2015;141:353–359.
Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol. 2014;113:158–165.
Maffione AM, Chondrogiannis S, Marzola MC, et al. Biological target volume overlapping segmentation system method for avoiding false-positive PET findings in assessing response to neoadjuvant chemoradiation therapy in rectal cancer. Clin Nucl Med. 2014;39:e215–e219.
Cerny M, Dunet V, Rebecchini C, et al. Response of locally advanced rectal cancer (LARC) to radiochemotherapy: DW-MRI and multiparametric PET/CT in correlation with histopathology. Nuklearmedizin. 2019;58:28–38.
Li YL, Wu LM, Chen XX, et al. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer? J Dig Dis. 2014;15:525–537.
Petrillo A, Fusco R, Petrillo M, et al. Standardized index of shape (DCE-MRI) and standardized uptake value (PET/CT): two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile. Oncotarget. 2017;8:8143–8153.
Giannini V, Mazzetti S, Bertotto I, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. Eur J Nucl Med Mol Imaging. 2019;46:878–888.
Ferrari M, Travaini LL, Ciardo D, et al. Interim 18 FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: a systematic review. Crit Rev Oncol Hematol. 2017;113:28–42.
Maffione AM, Chondrogiannis S, Capirci C, et al. Early prediction of response by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal cancer: a systematic review. Eur J Surg Oncol. 2014;40:1186–1194.
Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med. 2006;47:1241–1248.
Avallone A, Aloj L, Caracò C, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging. 2012;39:1848–1857.
Gu J, Khong PL, Wang S, et al. Combined use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in treatment response for preoperative chemoradiation therapy in locally invasive rectal cancers. Clin Nucl Med. 2013;38:e226–e229.
Goldberg N, Kundel Y, Purim O, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol. 2012;7:124.
Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24:191–200.
Janssen MH, Ollers MC, van Stiphout RG, et al. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiother Oncol. 2010;94:151–155.
Herrmann K, Bundschuh RA, Rosenberg R, et al. Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol. 2011;13:1011–1019.
Guerra L, Niespolo R, Di Pisa G, et al. Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging. 2011;36:38–45.
Janssen MH, Öllers MC, van Stiphout RG, et al. PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys. 2012;82:871–876.
Bampo C, Alessi A, Fantini S, et al. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology. 2013;84:191–199.
Hatt M, van Stiphout R, le Pogam A, et al. Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET. Acta Oncol. 2013;52:619–626.
Bundschuh RA, Dinges J, Neumann L, et al. Textural parameters of tumor heterogeneity in 18F-FDG PET/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer. J Nucl Med. 2014;55:891–897.
Leccisotti L, Gambacorta MA, de Waure C, et al. The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging. 2015;42:657–666.
Habr-Gama A, São Julião GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019;62:802–808.
Guyot F, Faivre J, Manfredi S, et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol. 2005;16:756–761.
Seo SI, Lim SB, Yoon YS, et al. Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013;108:9–13.
Renfro LA, Grothey A, Kerr D, et al. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. Ann Oncol. 2015;26:950–958.
Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.
Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263–270.
Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–2516.
Sinaei M, Swallow C, Milot L, et al. Patterns and signal intensity characteristics of pelvic recurrence of rectal cancer at MR imaging. Radiographics. 2013;33:E171–E187.
Lambregts DM, Cappendijk VC, Maas M, et al. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol. 2011;21:1250–1258.
Maas M, Rutten IJ, Nelemans PJ, et al. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis: imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011;38:1560–1571.
Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. Int J Color Dis. 2013;28:1039–1047.
Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1–192, iii–iv.
Chan K, Welch S, Walker-Dilks C, et al. Evidence-based guideline recommendations on the use of positron emission tomography imaging in colorectal cancer. Clin Oncol (R Coll Radiol). 2012;24:232–249.
Yu T, Meng N, Chi D, et al. Diagnostic value of (18)F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. 2015;72:443–451.
Jadvar H, Colletti PM, Delgado-Bolton R, et al. Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J Nucl Med. 2017;58:2026–2037.
Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med. 2009;50:1036–1041.
Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014;311:1863–1869.
Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104:2658–2670.
Maffione AM, Lopci E, Bluemel C, et al. Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2015;42:152–163.
Gade M, Kubik M, Fisker RV, et al. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging. 2015;15:11.
NCCN Clinical Practice Guidelines in Oncology Rectal Cancer Version 2.2020. page REC-11. Available at: www.nccn.org. Accessed March 26, 2020.
Hu H, Huang J, Lan P, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial. BMC Cancer. 2018;18:1145.
Probst CP, Becerra AZ, Aquina CT, et al. Watch and wait?–Elevated pretreatment CEA is associated with decreased pathological complete response in rectal cancer. J Gastrointest Surg. 2016;20:43–52.
McKeown E, Nelson DW, Johnson EK. Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer. 2014;5:31–43.
Buijsen J, van Stiphout RG, Menheere PP, et al. Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: a prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiother Oncol. 2014;111:237–242.
Rosati G, Ambrosini G, Barni S, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27:274–280.
Tarantino I, Warschkow R, Schmied BM. Predictive value of CEA for survival in stage I rectal cancer: a population-based propensity score-matched analysis. J Gastrointest Surg. 2016;20:1213–1222.
Cho WK, Choi DH, Park HC, et al. Elevated CEA is associated with worse survival in recurrent rectal cancer. Oncotarget. 2017;8:105936–105941.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624–630.
Shinkins B, Nicholson BD, James T, et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health Technol Assess. 2017;21:1–60.